Last reviewed · How we verify
Mencevax® ACWY
Mencevax ACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y.
Mencevax ACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | Mencevax® ACWY |
|---|---|
| Also known as | Neisseria meningitidis serogroups A, C, W and Y vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains polysaccharide capsular antigens from Neisseria meningitidis serogroups A, C, W, and Y conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune responses. Upon administration, it triggers both humoral and cellular immunity, leading to the production of bactericidal antibodies that protect against invasive meningococcal disease caused by these four serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Headache
- Myalgia
- Fatigue
- Fever
Key clinical trials
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine (PHASE2)
- Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mencevax® ACWY CI brief — competitive landscape report
- Mencevax® ACWY updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI